奥密克戎变异株 BA.2.86 对 SARS-CoV-2 的中和逃逸
Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
机构信息
Beth Israel Deaconess Medical Center, Boston, MA, USA.
Los Alamos National Laboratories, Santa Fe, NM, USA.
出版信息
Vaccine. 2023 Nov 13;41(47):6904-6909. doi: 10.1016/j.vaccine.2023.10.051. Epub 2023 Oct 21.
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that BA.2.86 might evade neutralizing antibodies (NAbs) induced by vaccination or infection. In this study, we show that NAb titers are substantially lower to BA.2.86 compared with BA.2 but are similar or slightly higher than to other current circulating variants, including XBB.1.5, EG.5.1, and FL.1.5.1. Moreover, NAb titers against all these variants were higher in vaccinated individuals with a history of XBB.1.5 infection compared with vaccinated individuals with no history of XBB.1.5 infection, suggesting the potential utility of the monovalent XBB.1.5 mRNA boosters.
摘要
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的变异株 BA.2.86 与 BA.2 和 XBB.1.5 相比，在刺突蛋白上有超过 30 个突变，这增加了 BA.2.86 可能逃避疫苗接种或感染诱导的中和抗体 (NAb) 的可能性。在这项研究中，我们表明，与 BA.2 相比，针对 BA.2.86 的 NAb 滴度显著降低，但与其他当前流行的变异株（包括 XBB.1.5、EG.5.1 和 FL.1.5.1）相似或略高。此外，与没有 XBB.1.5 感染史的接种者相比，有 XBB.1.5 感染史的接种者对所有这些变异株的 NAb 滴度更高，这表明单价 XBB.1.5 mRNA 加强针的潜在效用。
相似文献
1
Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
Vaccine. 2023 Nov 13;41(47):6904-6909. doi: 10.1016/j.vaccine.2023.10.051. Epub 2023 Oct 21.
2
An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant.
EBioMedicine. 2025 Jun 6;117:105794. doi: 10.1016/j.ebiom.2025.105794.
3
Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
J Med Virol. 2024 Mar;96(3):e29520. doi: 10.1002/jmv.29520.
4
Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history.
Microbiol Spectr. 2025 Jul 17:e0290724. doi: 10.1128/spectrum.02907-24.
5
Mucosal and Serum Neutralization Immune Responses Elicited by COVID-19 mRNA Vaccination in Vaccinated and Breakthrough-Infection Individuals: A Longitudinal Study from Louisville Cohort.
Vaccines (Basel). 2025 May 24;13(6):559. doi: 10.3390/vaccines13060559.
6
SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.
J Med Virol. 2024 Mar;96(3):e29527. doi: 10.1002/jmv.29527.
7
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.
Vaccine. 2025 May 10;55:127046. doi: 10.1016/j.vaccine.2025.127046. Epub 2025 Apr 2.
8
Differential immunity induced by Omicron sublineages in naïve and vaccine breakthrough infections.
Sci Rep. 2025 Jul 3;15(1):23718. doi: 10.1038/s41598-025-07702-2.
9
Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection.
Commun Med (Lond). 2025 Jun 20;5(1):243. doi: 10.1038/s43856-025-00943-2.
10
Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
PLoS Med. 2023 Jun 29;20(6):e1004157. doi: 10.1371/journal.pmed.1004157. eCollection 2023 Jun.
引用本文的文献
1
SARS-CoV-2 Pneumonia: Advances in Diagnosis and Treatment.
Microorganisms. 2025 Jul 31;13(8):1791. doi: 10.3390/microorganisms13081791.
2
Conformational Dynamics and Binding Interactions of SARS-CoV-2 Spike Protein Variants: Omicron, XBB.1.9.2, and EG.5.
J Chem Inf Model. 2025 Jul 11. doi: 10.1021/acs.jcim.5c00308.
3
RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera.
J Virol. 2025 Jul 22;99(7):e0053125. doi: 10.1128/jvi.00531-25. Epub 2025 Jul 3.
4
Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant.
Virol J. 2025 May 24;22(1):162. doi: 10.1186/s12985-025-02737-3.
5
Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3.
mBio. 2025 Apr 29:e0350324. doi: 10.1128/mbio.03503-24.
6
RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera.
bioRxiv. 2025 Mar 11:2025.03.11.642476. doi: 10.1101/2025.03.11.642476.
7
The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells.
Front Immunol. 2025 Mar 12;16:1513175. doi: 10.3389/fimmu.2025.1513175. eCollection 2025.
8
Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.
J Virol. 2025 Apr 15;99(4):e0024225. doi: 10.1128/jvi.00242-25. Epub 2025 Mar 26.
9
SARS-CoV-2 Fusion Peptide-Directed Antibodies Elicited by Natural Infection Mediate Broad Sarbecovirus Neutralization.
medRxiv. 2025 Mar 5:2025.03.01.25323010. doi: 10.1101/2025.03.01.25323010.
10
Designed mosaic nanoparticles enhance cross-reactive immune responses in mice.
Cell. 2025 Feb 20;188(4):1036-1050.e11. doi: 10.1016/j.cell.2024.12.015. Epub 2025 Jan 23.
本文引用的文献
1
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.
Nature. 2023 Dec;624(7992):639-644. doi: 10.1038/s41586-023-06750-w. Epub 2023 Oct 23.
2
Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
Emerg Microbes Infect. 2023 Dec;12(2):2271089. doi: 10.1080/22221751.2023.2271089. Epub 2023 Oct 26.
3
Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86.
Lancet Infect Dis. 2023 Nov;23(11):e457-e459. doi: 10.1016/S1473-3099(23)00573-X. Epub 2023 Sep 19.
4
Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant.
Lancet Infect Dis. 2023 Nov;23(11):e460-e461. doi: 10.1016/S1473-3099(23)00575-3. Epub 2023 Sep 18.
5
Project NextGen - Defeating SARS-CoV-2 and Preparing for the Next Pandemic.
N Engl J Med. 2023 Aug 31;389(9):773-775. doi: 10.1056/NEJMp2307867. Epub 2023 Jul 26.
6
Durability of Bivalent Boosters against Omicron Subvariants.
N Engl J Med. 2023 May 11;388(19):1818-1820. doi: 10.1056/NEJMc2302462. Epub 2023 Apr 12.
7
Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1.
N Engl J Med. 2023 Feb 16;388(7):662-664. doi: 10.1056/NEJMc2214314. Epub 2023 Jan 18.
8
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.
N Engl J Med. 2022 Jul 7;387(1):86-88. doi: 10.1056/NEJMc2206576. Epub 2022 Jun 22.
9
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
10
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.
Cell Host Microbe. 2021 May 12;29(5):819-833.e7. doi: 10.1016/j.chom.2021.03.005. Epub 2021 Mar 12.
Zotero 插件